Novartis pays $15M upfront to license Voyager program; Boehringer advances geographic atrophy drug

Plus, news about Jnana Therapeutics, Vaxcyte, C-Further, Genprex, PharmaEssentia, FORUS Therapeutics, Pharma Two B and Hepion:

Novartis licenses Voyager program: Voyager will get $15 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA to investigate presence of metals in tampons

Dive Brief: The Food and Drug Administration said Tuesday it is studying the presence of metals in tampons to understand if there are health risks.

September 11, 2024

Merck KGaA eyes more manufacturing M&A as it faces headwinds in China

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales expectations for its life science

October 18, 2024

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated

October 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.